摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-Ethyl-2-phenylpiperazine | 5271-31-8

中文名称
——
中文别名
——
英文名称
1-Ethyl-2-phenylpiperazine
英文别名
——
1-Ethyl-2-phenylpiperazine化学式
CAS
5271-31-8
化学式
C12H18N2
mdl
——
分子量
190.28
InChiKey
RMLRVZUMYGPBGG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    14
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    15.3
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    (+/-)-1-BOC-4-ethyl-3-phenyl-piperazine 、 hydrochloric acid diethyl ether 、 盐酸乙醚 、 hydrochloride salt 作用下, 以 二氯甲烷1,4-二氧六环 为溶剂, 反应 20.0h, 以to give the title compound (231 mg) as its hydrochloride salt的产率得到1-Ethyl-2-phenylpiperazine
    参考文献:
    名称:
    HETEROCYCLIC DERIVATIVES AS HDAC INHIBITORS
    摘要:
    这项发明涉及到新的组蛋白去乙酰化酶抑制剂,其一般式为(I),其中:虚线是可选的附加键;R1是氢、卤素、C1-C6烷基、C1-C6烷氧基、C1-C6卤代烷基或C1-C6卤代烷氧基;R2、R3独立地是氢、C1-C6烷基、芳基或者与它们所结合的碳原子形成桥接的双环环或融合的杂环;X是CH或氮;Y是键、氧、(CH2)mCR4R5(CH2)n或(CH2)oNR6(CH2)p;m、n、o、p、R4、R5和R6如规范中所定义;以及其药物可接受的盐。
    公开号:
    US20110105474A1
点击查看最新优质反应信息

文献信息

  • [EN] NICOTINIC ACETYLCHOLINE RECEPTOR SILENT AGONISTS<br/>[FR] AGONISTES SILENCIEUX DU RÉCEPTEUR NICOTINIQUE D'ACÉTYLCHOLINE
    申请人:THE UNIV OF FLORIDA RES FOUND INC
    公开号:WO2017066558A1
    公开(公告)日:2017-04-20
    Derivatives of N,N-diethyl-N'- phenyl-piperazine, a silent agonist of the mammalian α7 nicotinic acetylcholine receptor, are provided. These silent agonists control the desensitization state of the receptor. Further provided are pharmaceutical compositions that allow the administration of the silent agonists of the disclosure to a subject animal or human in need of treatment for a pathological condition arising from such as inflammation. The novel silent agonists also may be co-administered to a patient simultaneously or consecutively with a type II positive allosteric modulator to modulate the activity of the receptor.
    N,N-二乙基-N'-苯基哌嗪的衍生物,作为哺乳动物α7尼古丁乙酰胆碱受体的沉默激动剂,已提供。这些沉默激动剂控制受体的耗散状态。还提供了允许将上述沉默激动剂给予需要治疗由炎症等病理状况引起的动物或人类的药物组合物。这种新型沉默激动剂也可以与II型正向变构调节剂同时或连续给予患者,以调节受体的活性。
  • Heterocyclic derivatives as HDAC inhibitors
    申请人:DAC S.r.l.
    公开号:EP2133334A1
    公开(公告)日:2009-12-16
    This invention is related to new histone deacetylase inhibitors according to the general formula (I) wherein: the dotted line is an optional additional bond; R1 is hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl or C1 C6 haloalkoxy; R2, R3 are, independently, hydrogen; C1-C6 alkyl; aryl; or taken together with the carbon atoms to which they are bound form a bridged bicyclic ring or a fused heterocycle; X is CH or nitrogen; Y is a bond, oxygen, (CH2)mCR4R5(CH2)n, or (CH2)oNR6(CH2)p; m, n, o, p, R4, R5 and R6 are as further defined in the specification; and pharmaceutical acceptable salts thereof.
    这项发明涉及新的组蛋白去乙酰化酶抑制剂,其通式如下(I):其中:虚线是可选的额外键;R1是氢、卤素、C1-C6烷基、C1-C6烷氧基、C1-C6卤烷基或C1-C6卤烷氧基;R2、R3分别是氢、C1-C6烷基、芳基;或者与它们相结合的碳原子形成桥接的双环或融合的杂环;X是CH或氮;Y是键、氧、(CH2)mCR4R5(CH2)n、或(CH2)oNR6(CH2)p;m、n、o、p、R4、R5和R6如规范中进一步定义;以及其药用可接受盐。
  • [EN] NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES<br/>[FR] AGONISTES DU RECEPTEUR DE NICOTINE POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES
    申请人:UNIV LAVAL
    公开号:WO2006005195A1
    公开(公告)日:2006-01-19
    This invention relates to the use of nicotine receptor agonists or analogs or derivatives thereof for treating inflammatory pulmonary diseases. The invention further relates to pharmaceutical compositions comprising nicotine receptor agonists or analogs or derivatives thereof. Novel compounds of formula wherein R1 ,R2 ,Xa and Ya are as defined herein are also provided.
    本发明涉及使用尼古丁受体激动剂或类似物或其衍生物治疗炎症性肺部疾病。本发明还涉及包含尼古丁受体激动剂或类似物或其衍生物的制药组合物。还提供了公式中R1,R2,Xa和Ya如定义所述的新化合物。
  • [EN] 3-CYANOQUINOLINES,3-CYANO-1,6-NAPHTHYRIDINES, AND 3-CYANO-1,7-NAPHTHYRIDINES AS PROTEIN KINASE INHIBITORS<br/>[FR] 3-CYANOQUINOLINES,3-CYANO-1,6-NAPHTHYRIDINES ET 3-CYANO-1,7-NAPHTHYRIDINES UTILISEES COMME INHIBITEURS DE PROTEINEKINASE
    申请人:AMERICAN HOME PROD
    公开号:WO2001072711A1
    公开(公告)日:2001-10-04
    Compounds of Formula (I), having the structure or a pharmaceutically salt thereof are useful as antineoplastic agents and in the treatment of osteoporosis and polycystic kidney disease.
    具有结构式(I)或其药物盐的化合物在抗肿瘤药物和治疗骨质疏松症和多囊肾病方面是有用的。
  • Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
    申请人:Hutchison Alan
    公开号:US20050182068A1
    公开(公告)日:2005-08-18
    Melanin concentrating hormone receptor ligands (especially 1-benzyl-4-aryl-piperazines, 1-benzyl-4-aryl-piperidines and related compounds), capable of modulating MCH receptor activity, are provided. Such ligands may be used to modulate MCH binding to MCH receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of metabolic, feeding and sexual disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting MCH receptors (e.g., receptor localization studies).
    提供了黑色素浓集激素受体配体(尤其是1-苄基-4-芳基哌嗪,1-苄基-4-芳基哌啶和相关化合物),能够调节MCH受体活性。这样的配体可用于调节体内或体外MCH结合到MCH受体,并且在人类、家养伴侣动物和家畜动物的多种代谢、进食和性疾病治疗中特别有用。提供了用于治疗此类疾病的制药组合物和方法,以及用于检测MCH受体的配体的方法(例如受体定位研究)。
查看更多